Table 1.
Identifying high-risk human leukocyte antigen (HLA) alleles in Sjögren’s syndrome (SjS).
| Country of Origin/Population | HLA Alleles Connotation | Auto-Antibodies Identified | References |
|---|---|---|---|
| U.S.A./American Caucasian | HLA-B8 | ND * | [36] |
| U.S.A./American Caucasian | HLA-Dw3 | ND * | [22] |
| U.S.A./American Caucasian | HLA-Dw3-HLA-B8 | ND * | [12] |
| U.S.A./American Caucasian | HLA-DRw3-HLA-B8 | Antinuclear antibodies Ro60 | [37] |
| U.S.A./American Caucasian | HLA-DRw3-HLA-B8 | Ro52 | [18] |
| U.S.A./American Caucasian | HLA-DRw52 | SS-A | [38] |
| Japan/Japanese population | HLA-DRB1*0301 | SS-A and SS-B | [39] |
| HLA-DRB3*0101 | |||
| HLA-DQA1*0501/DQB1*0201 | |||
| Japan/Japanese population | HLA-DRB1*0405 | SS-A and SS-B | [39] |
| HLA-DRB4*0101 | |||
| HLA-DQA1*0301/DQB1*0401 | |||
| Japan/Japanese population | HLA-DRw53 | Ro/SS-A and La/SS-B | [40] |
| Japan/Japanese population | HLA-DRB1*8032/DQA1*0103/DQB1*0601 | Ro/SS-A and La/SS-B | [39,41] |
| HLA-DRB1*8032 | |||
| HLA-DRB1*0405-DRB4*0101 | |||
| HLA-DQA1*0301 | |||
| HLA-DQB1*0401 | |||
| China/Chinese population | HLA-DRB1*0803 | SS-A and SS-B | [39] |
| HLA-DQA1*0103/DQB1*0601 | |||
| Mexico/Mexican population | HLA-DRB1*01:01 | Ro/SS-A and La/SS-B | [42] |
| HLA-B*35:01 | |||
| Colombia/Mestizo Colombian population | HLA-DRB1*0301 | Ro/SS-A and La/SS-B | [26,32,43] |
| HLA-DQB1*0201 | |||
| Israel/Israeli Jewish/Greek | HLA-DQA1*001 | SS-A, and SS-B | [44] |
| HLA-DQA1*0201/DQB1*0501-Jewish | |||
| HLA-DQA1*0501-Greek | |||
| Greece/Greek population | HLA-DRB1*0301 | Ro/SSA and anti-La/SSB |
[45] |
| Spain/Spanish population | HLA-Cw7 | Ro/SSA and anti-La/SSB | [46] |
| HLA- DRB1*0301 | |||
| HLA-DR11 | |||
| France/French population | HLA-DRB1*1501 | ND * | [33] |
| HLA- DRB1*0301 | |||
| HLA-DQB1*0201 | |||
| HLA-DQB1*0602 | |||
| France/French population | HLA-DRB1*0301 | anti-SSA and/or anti-SSB | [31] |
| HLA-DQB1*02 | |||
| Italy/Italian population | HLA-DRB1*0301 | anti-Ro/SSA | [47] |
| Denmark/Danish population | HLA-Dw2 | ND * | [23] |
| Denmark/Danish population | HLA-DQA1*0501 | anti-SSA and/or anti-SSB | [48] |
| HLA-DQB1*0201 | |||
| HLA-DQA1*0301 | |||
| Finland/Finnish population | HLA-DRB1*0301 | anti-SS-A/Ro and anti-SS-B/La | [49] |
| HLA-DQA1*0501 | |||
| HLA-DQB1*0201 | |||
| Norway/Norwegian Caucasian population | HLA-DRB1*0301 | Ro/SSA and La/SSB | [50] |
| Norway/Norwegian Caucasian population | HLA-DRB1*0301 | anti-La/SSB strong positive association with DQA1*0501 anti-Ro/SSA and anti-La/SSB autoantibody response was positively associated with DRB1*03, DQB1*02 and DRB1*03/DRB1*15-DQB1*02/DQB1*0602 |
[19] |
| HLA-DQB1*02 | |||
| HLA-DQA1*0501 | |||
| United Kingdom/British Caucasian population | HLA-DRB1*0301 | Ro/SSA and La/SSB | [51] |
| HLA-DRw52 | |||
| Australia/Australian population | HLA-DRB1*0301 | Ro/SSA and La/SSB | [16] |
| HLA-DQA1*0501 | |||
| HLA-DQB1*02 | |||
| Tunisian population | HLA-DQB1 CAR1/CAR2 | ND * | [52] |
| European and African American population | HLA-DQB1*0201 | SSA | [53] |
| HLA-DQA1*0101 |
ND *—not determined.